Evidence map›Paper›PMID 35805000›Full record

ReviewCancers2022

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma.

Diede A G van Bladel, Wendy B C Stevens, Michiel van den Brand, Leonie I Kroeze, Patricia J T A Groenen, J Han J M van Krieken, Konnie M Hebeda, Blanca Scheijen

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Diagnostic and prognostic molecular pathology of lymphoid malignancies.Virchows Archiv : an international journal of pathology · 2024
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Diede A G van BladelRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-4289-2807
Wendy B C StevensRadboud University Medical Center, Department of Hematology, 6525 GA Nijmegen, The Netherlands.
Michiel van den BrandRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
Leonie I KroezeRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
Patricia J T A GroenenRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
J Han J M van KriekenRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
Konnie M HebedaRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.
Blanca ScheijenRadboud University Medical Center, Department of Pathology, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0001-8029-9230
Radboud University Nijmegen · NL

Funding

Dutch Cancer Society 11137
6 · The paper itself

Abstract

Classical Hodgkin lymphoma (cHL) represents a B-cell lymphoproliferative disease characterized by clonal immunoglobulin gene rearrangements and recurrent genomic aberrations in the Hodgkin Reed-Sternberg cells in a reactive inflammatory background. Several methods are available for the molecular analysis of cHL on both tissue and cell-free DNA isolated from blood, which can provide detailed information regarding the clonal composition and genetic alterations that drive lymphoma pathogenesis. Clonality testing involving the detection of immunoglobulin and T cell receptor gene rearrangements, together with mutation analysis, represent valuable tools for cHL diagnostics, especially for patients with an atypical histological or clinical presentation reminiscent of a reactive lesion or another lymphoma subtype. In addition, clonality assessment may establish the clonal relationship of composite or subsequent lymphoma presentations within one patient. During the last few decades, more insight has been obtained on the molecular mechanisms that drive cHL development, including recurrently affected signaling pathways (e.g., NF-κB and JAK/STAT) and immune evasion. We provide an overview of the different approaches to characterize the molecular composition of cHL, and the implementation of these next-generation sequencing-based techniques in research and diagnostic settings.

Indexed as

cell-free DNAclassical Hodgkin lymphomaclonality assessmentmutation analysisnext-generation sequencing

Identifiers

PMID35805000
PMCPMC9264882
OpenAlexW4283762038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.